alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 351–375 of 530 studies · free to read (page 15 of 22) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 530 studies tagged mild-cognitive — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Remote Neuropsychological Assessment in Rural American Indians with and without Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists 2016-05-30

The sample consisted of 84 participants from the Choctaw Nation in Oklahoma, including 53 females and 31 males [M age = 64.89 (SD = 9.73), M education = 12.58 (SD = 2.35)]. 2 key findings →

Participants: 84 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mobile Technology for Cognitive Assessment of Older Adults: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Innovation in aging 2019-01-01

Twenty-nine articles met our inclusion criteria and were categorized into 3 groups as follows: (a) mobile versions of existing article or computerized neuropsychological tests; (b) new cognitive tests developed specifically for mobile platforms; and (c) the use of new types of data for cognitive assessment. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Digital Biomarkers for the Early Detection of Mild Cognitive Impairment: Artificial Intelligence Meets Virtual Reality

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in human neuroscience 2020-07-24

Elderly people affected by Mild Cognitive Impairment (MCI) usually report a perceived decline in cognitive functions that deeply impacts their quality of life. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of cognitive impairment via deep learning trained with multi-center neuropsychological test data

✓ Peer-reviewed alzhub usefulness score 45 out of 100. BMC medical informatics and decision making 2019-11-21

The machine learning algorithm for NPTs has suggested potential use as a reference in differentiating cognitive impairment in the clinical setting. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropathologic alterations in mild cognitive impairment: a review

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer's disease : JAD 2010-01-01

Mild cognitive impairment (MCI), the earliest clinically detectable phase of the trajectory toward dementia and Alzheimer's disease (AD), led to the need for even earlier detection and prevention of AD. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer's research & therapy 2013-04-29

Advances in AD biomarker research have demonstrated changes in amyloid-beta (Aβ), brain metabolism and other pathophysiologies prior to the onset of memory loss, with some markers possibly changing one or two decades earlier. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Screening utility of the Montreal Cognitive Assessment (MoCA): in place of--or as well as--the MMSE?

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International psychogeriatrics 2011-10-03

This aim of this study was to assess the clinical utility of the Montreal Cognitive Assessment (MoCA) as a screening instrument for cognitive impairment in patients referred to a memory clinic, alone and in combination with the Mini-Mental State Examination (MMSE). 4 key findings →

Participants: 150 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of Normative Adjustments to the Montreal Cognitive Assessment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2018-09-21

499 adults 48 to 91 years-old enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) and were administered the MoCA during baseline. 4 key findings →

Participants: 499 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of dementia and mild cognitive impairment in the Mexican population: evidence from Mex-Cog, a harmonized cognitive assessment protocol study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journals of Gerontology Series B 2025-12-17

We estimated the prevalence of dementia at 6.7% [95% confidence interval (CI): 5.4-8.0] and MCI at 10% (95% CI: 8.7-11.7). 5 key findings →

Participants: 1,629 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine learning approaches to racial/ethnic differences in social determinants of mild cognitive impairment and its progression to dementia in the All of Us Research Program

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journals of Gerontology Series B 2025-09-19

MCI prevalence was comparable across groups (7.5%-8.0%), but progression to dementia varied (9.4% Black vs. 11.4% Other). 5 key findings →

Participants: 83,180 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Screening tools for subjective cognitive decline and mild cognitive impairment based on task-state prefrontal functional connectivity: a functional near-infrared spectroscopy study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. NeuroImage 2025-03-07

Statistical analysis revealed a trend toward more impaired prefrontal FC with declining cognitive function. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment and neuropsychological examination

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in Psychology 2025-11-06

The paper discusses according to prevailing diagnostic systems and algorithms, which cognitive domains that are relevant to investigate, which tests that may be relevant, what kind of norms have satisfactory quality, which cut-off scores do best balance sensitivity and specificity in a neurodiagnostic context, and what kind of conclusions and recommendations that can be drawn from neuropsychological findings. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Managed Care & Specialty Pharmacy 2025-07-24

< 0.0001) were significantly higher for the MCI cohort. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence and correlates of the head turning sign in mild cognitive impairment and dementia due to neurodegenerative, chronic cerebrovascular, and mixed etiologies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer s Disease 2025-02-16

In patients with cognitive impairment due to diverse causes, the HTS might occur regardless of MCI versus dementia status and across different etiologies. 4 key findings →

Participants: 121 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Usability and feasibility of INFORMA platform for computerized cognitive stimulation in mild cognitive impairment and early dementia: an 8-week multicenter study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Aging Clinical and Experimental Research 2026-03-13

Of 219 completing participants (mean age 73.5 years), the mean SUS score was 82.0 (95% CI: 80.3-83.8), with 84% exceeding the usability threshold (SUS score > 68). 5 key findings →

Participants: 241 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Risk factors for the progression of mild cognitive impairment to dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Clinics in geriatric medicine 2013-11-01

The increasing prevalence of cognitive impairment among the older adult population warrants attention to the identification of practices that may minimize the progression of early forms of cognitive impairment, including the transitional stage of mild cognitive impairment (MCI), to permanent stages of dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Optimizing Neuropsychological Assessments for Cognitive, Behavioral, and Functional Impairment Classification: A Machine Learning Study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Behavioural neurology 2017-01-31

Subjects with Alzheimer's disease (AD) show loss of cognitive functions and change in behavioral and functional state affecting the quality of their daily life and that of their families and caregivers. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine-learning techniques for building a diagnostic model for very mild dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. NeuroImage 2010-04-09

Many researchers have sought to construct diagnostic models to differentiate individuals with very mild dementia (VMD) from healthy elderly people, based on structural magnetic-resonance (MR) images. 1 key finding →

Participants: 83 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progression of mild cognitive impairment to dementia: a challenge to current thinking

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The British journal of psychiatry : the journal of mental science 2006-11-01

Further long-term studies are needed to examine the time-dependent evolution from mild cognitive impairment to dementia and to establish age-specific conversion rates during lifetime. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events